- Open Access
The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion
© Furmanova-Hollenstein et al.; licensee BioMed Central Ltd. 2013
Received: 6 November 2012
Accepted: 23 April 2013
Published: 30 April 2013
Ionizing radiation (IR) in combination with microtubule stabilizing agents (MSA) is a promising combined treatment modality. Supra-additive treatment responses might result from direct tumor cell killing and cooperative indirect, tumor cell-mediated effects on the tumor microenvironment. Here we investigated deregulation of matrix metalloproteinase (MMP) activity, as an important component of the tumor microenvironment, by the combined treatment modality of IR with the clinically relevant MSA patupilone.
Expression, secretion and activity of MMPs and related tissue inhibitors of metalloproteinases (TIMPs) were determined in cell extracts and conditioned media derived from human fibrosarcoma HT1080 and human glioblastoma U251 tumor cells in response to treatment with IR and the MSA patupilone. Treatment-dependent changes of the invasive capacities of these tumor cell lines were analysed using a Transwell invasion assay. Control experiments were performed using TIMP-directed siRNA and TIMP-directed inhibitory antibodies.
Enzymatic activity of secreted MMPs was determined after treatment with patupilone and irradiation in the human fibrosarcoma HT1080 and the human glioblastoma U251 tumor cell line. IR enhanced the activity of secreted MMPs up to 2-fold and cellular pretreatment with low dose patupilone (0.05-0.2 nM) counteracted specifically the IR-induced MMP activity. The cell invasive capacity of HT1080 and U251 cells was increased after irradiation with 2 Gy by 30% and 50%, respectively, and patupilone treatment completely abrogated IR-induced cell invasion. Patupilone did not alter the level of MMP expression, but interestingly, the protein level of secreted TIMP-1 and TIMP-2 was lower after combined treatment than after irradiation treatment alone. Furthermore, siRNA depletion of TIMP-1 or TIMP-2 prevented IR-mediated induction of MMP activity and cell invasion.
These results indicate that patupilone counteracts an IR-induced MMP activation process by the reduction of secreted TIMP-1 and TIMP-2 proteins, which are required for activation of MMPs. Since IR-induced MMP activity could contribute to tumor progression, treatment combination of IR with patupilone might be of great clinical benefit for tumor therapy.
Interference with microtubular (MT) function represents a clinically relevant anticancer strategy, as demonstrated by the use of taxanes for the treatment of a wide variety of human malignancies [1–3]. Epothilones are nontaxoid MSAs of bacterial origin, which share the same binding site on β-tubulin with taxanes [4, 5] and also promote tubulin polymerization and stabilization of already formed MTs . Members of the epothilone family, including patupilone (epothilone B), have been tested in multiple clinical trials [7–13], Combined application of patupilone with ionizing radiation (IR) is a promising combined treatment modality for cancer therapy, as previously investigated in our laboratory in different tumor models such as lung and colon adenocarcinoma and medulloblastoma. The combined treatment modality results in strong supra-additive growth inhibition of murine tumor xenografts [14–16]. Interestingly though, combined cytotoxicity is much less pronounced on the cellular level in vitro, indicating that an additional effect occurs on the level of the tumor microenvironment. Further investigations revealed that patupilone treatment inhibits VEGF-secretion from the tumor cells thereby contributing to the supra-additive cytotoxicity of the combined treatment modality observed in vivo.
Microtubule interference with MSA could deregulate the secretion of biologically active factors [14, 17, 18]. We recently demonstrated that patupilone counteracts stress-induced VEGF expression and secretion from patupilone-sensitive tumor cells . Furthermore, MSA could disturb the secretion of matrix metalloproteinase thereby affecting the tumor microenvironment (see below) [20–22].
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases with a broad variety of substrates including components of the extracellular matrix and growth factors, such as the transforming growth factor β (TGF- β). MMPs play an important role in cell survival, apoptosis, angiogenesis, matrix remodelling and metastasis and are regulated at several levels including transcriptional and posttranslational mechanisms and by endogenous tissue inhibitors of metalloproteinases (TIMPs) [23–25]. TIMPs, a family of proteins containing 4 members, TIMP1-4, inhibit MMP-activity by binding to the catalytic domain of active MMPs. However, TIMP-2 is also known to be a co-activator of MMP-2 zymogen in an MT1-MMP (MMP-14)-dependent proMMP-2 activation process . Additionally, TIMPs have MMP independent biological functions, including mitogenic  and pro- and anti-apoptotic functions [28, 29]. MMPs and TIMPs are secreted by tumor-associated stromal and cancer cells and are important components of the tumor microenvironment. Secretion of MMPs and TIMPs is partially executed in vesicles along the MT-cytoskeleton and is therefore a potential target for MSAs. Overexpression of MMPs and TIMPs is associated with a poor survival prognosis for almost all tumor types . In preclinical and clinical studies, IR was demonstrated to upregulate MMPs [30, 31], and enhanced levels of MMPs were detected in patients with lung and breast cancer after radiotherapy . Thus, IR might contribute to a potential prometastatic effect.
Here we investigated the effect of patupilone and IR on MMP function in vitro. We demonstrated that patupilone inhibits both IR-induced MMP activity and IR-induced cell invasion of human fibrosarcoma and glioma cell lines. Furthermore, we analysed the mechanisms of the inhibitory effect of patupilone and demonstrated that patupilone counteracts IR-upregulated MMP-activity by interfering with TIMP-1 and TIMP-2 secretion.
The human fibrosarcoma cells HT1080 (ATCC No CCL-121) were grown in IMDM media. Human glioma cells U251 was cultured in DMEM media. Media was supplemented with 10% (v/v) FCS and 1% (v/v) penicillin-streptomycin. All cell culture media and supplements were obtained from Gibco (Invitrogen). Cells were grown at 37°C in a 5% CO2 humidified atmosphere. For control of identity, all cells throughout the course of the studies were monitored for cell morphology and growth pattern. Cells were cultured for not more than 10 passages.
To prepare conditioned cell culture media (CM) cells were pretreated with or without patupilone for 24 h and sham-treated or irradiated with the indicated doses of IR. The cell culture media was discarded 1 h after irradiation and cells were incubated for an additional 24 h in serum-free Ultraculture medium (Lonza, Fischer Scientific). Conditioned cell culture medium was collected, centrifuged at 10’000 g for 5 min at 4°C and supernatants were stored at −80°C.
Transfection was performed using Lipofectamine 2000 (Invitrogen). siRNAs for downregulation of human TIMP-1 (GenBank BC000866.1) and human TIMP-2 (GenBank BC052605.1) were synthesized by Microsynth (Switzerland). siRNA against firefly luciferase (siLuc) was used for control transfection. siRNA sequences (5′-3′):
siTIMP-1#1 GAUGUAUAAAGGGUUCCAAdTdT 
siTIMP-2#1 GGCACAUUAUGUAAACAUAdTdT 
siLuc CGTACGCGGAATACTTCGAdTdT (Microsynth).
siRNAs were designed using Microsynth siRNA Design Tool.
Irradiation was performed at room temperature using an Xstrahl 200 kV X-ray unit (Gulmay Medical) at 1 Gy/min. Patupilone was provided by Novartis Pharma AG (Basel, Switzerland).
Clonogenic survival assay
Clonogenic survival assay was performed as described previously . 24 h after plating, cells were treated with increasing concentrations of patupilone and irradiated 24 h later. Colonies were allowed to grow under normal cell culture conditions for 7–10 days before fixation with methanol/acetic acid (75%/25% v/v) and staining with 2% crystal violet. Colonies with more than 50 cells were counted manually. For the determination of the synergistic effect, the earlier described model of synergy was used .
MMP activity assay
MMP activity in the CM was determined using a FRET-based MMP activity assay (SensoLyte MMP-2 assay kit, AnaSpec). According to the kit-description the peptide substrate can be cleaved by multiple MMPs and was used for the determination of pooled MMP activity. The substrate cleavage reaction was performed according to the manufacture’s instructions. The fluorescent signal was measured in a Tecan GENios spectrophotometer every hour for 14 hours. The acquired signal was adjusted to the cell number and presented as the initial velocity of the substrate cleavage reaction (V0), relative to control. V0 was determined as a slope of the curve – the fluorescent signal plotted versus time – using linear regression (GraphPad Software, Inc).
Transwell inserts (6.5 mm, 8 μm pores, Costar) were coated with Matrigel™ (Becton Dickinson). Complete cell culture media was used as attractant for migrating cells. 5’000 cells/insert for HT1080 cells and 8’000 cells/insert for U251 cell were seeded in 200 μL of serum-free media. Patupilone was added to cells at the moment of seeding and cells were irradiated 4 h thereafter. Cells were allowed to migrate for 24 h. For quantification, cells from the upper side of the insert were scraped away, inserts were fixed in Methanol/Acetic acid (75%/25%, v/v) and stained with DAPI. Invaded cells were counted manually under a fluorescent microscope or using the software (Imaris, Bitplane). Each experiment was carried out in quadruplicates.
Quantitative real time PCR (qRT-PCR)
The total mRNA was isolated with RNeasy Plus Mini Kit (Qiagen). Reverse transcriptase reaction was conducted with 1 μg of mRNA with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR was performed with Fast SYBR Green Master Mix on 7900H PCR Instrument (Applied Biosystems). Data were analysed using RQ-manager software (Applied Biosystems) by employing ΔΔCt method. The following primers were used:
MMP-1 F: TGTGGACCATGCCATTGAGAA, R: TCTGCTTGACCCTCAGAGACC;
MMP-2 F: CTTCCGTCTGTCCCAGGAT, R: CCCCAT AGAGCTCCTGAATG;
MMP-3 F: GGGCCATCAGAGGAAATG, R: CACGGTTGGAGGGAAACCTA;
MMP-9 F: GGCCACTACTGTGCCTTTGAG, R: GATGGCGTCGAAGATGTTCAC;
MMP-14 F: TGGAGGAGACACCCACTTTGA, R: GCCACCAGGAAGATGTCATTTC;
TIMP-1 F: AGTGGCACTCATTGCTTGTG, R: TTTTCAGAGCCTTGGAGGAG;
TIMP-2 F: TTTTGCAATGCAGATGTAGTGAT, R: TCCTTCTCACTGACCGCTTT;
18srRNA F: ATGGCCGTTCTTAGTTGGTG, R: CGCTGAGCCAGTCAGTGTAG;
TBP F: CGGCTGTTTAACTTCGCTTC, R: TTCTTG GCAAACCAGAAACC.
Western blot was performed as described previously . The following antibodies were used: anti-TIMP-1 and −2 (neutralizing antibodies, R&D systems), anti-β-actin (Sigma). Western blot films were scanned with transillumination mode and the bands was quantified by Quantity One 4.6 software (Bio-Rad Laboratories).
Statistical analysis was performed using GraphPad Prism 3–5 software (GraphPad Software, Inc.). A comparison between the groups was performed using t-test. Results are plotted as mean ± SE; the level of significance was set at P < 0.05.
Patupilone inhibits IR-induced matrix metalloproteinase activity
Long-term clonogenic survival of the HT1080 cells was determined after treatment with increasing doses of IR and patupilone (Figure 1B). Importantly low dose treatment with IR (2 Gy) or patupilone (0.2 nM), alone did not reduce clonogenicity of these fibrosarcoma cells. 10 Gy of IR reduced clonogenic cell survival of these radiation resistant cells to an SF of 0.3, and combined treatment with patupilone primarily induced an additive anti-clonogenic effect (Figure 1B). The proliferative activity of these HT1080 cells was only minimally reduced after treatment with patupilone (0.2 nM) alone and in combination with irradiation (10 Gy) (Additional file 1: Figure S1). Thus, patupilone significantly counteracted IR-induced MMP activity independent of a putative, antiproliferative effect of these treatment modalities.
Patupilone does not regulate the expression of matrix metalloproteinases
To determine interference of patupilone with MMP transcription by other known inducers of MMP-activity, cells were treated with phorbol-12-myristate-13-acetate (PMA), a strong transcriptional inducer of MMPs [36, 37]. PMA-treatment upregulated MMP-9- and MMP-1-transcription by 13- and 5-fold, respectively. The proteolytic activity of MMPs, determined in the CM derived from PMA-treated cells, doubled after incubation with PMA (P = 0.0001). Pretreatment with patupilone did not counteract PMA-induced transcription (Figure 2B) but again diminished PMA-enhanced MMP-activity, as determined in CM derived from cells treated with PMA in combination with patupilone (P = 0.0001, Figure 2C).
Irradiation and patupilone-treatment might affect protein expression or secretion of matrix metalloproteinases. We therefore probed intra- and extracellular protein levels of MMPs (MMP-1, 2, 3, 9, 14) by western blotting and with gelatine zymography assays in case when no satisfactory antibody-based detection could be achieved. Since irradiation of HT1080 cells with 2 Gy only minimally increased MMP activity (Figure 1A) and mRNA levels (Figure 2A), experiments were performed with 10 Gy of irradiation. In cellular lysates derived from irradiated HT1080 cells only a minimal increase of MMP-9 protein level could be detected. On the other hand, in conditioned media, the protein level of all MMPs tested (MMP-2, 3) were slightly increased in response to irradiation (Additional file 2: Figure S2). These results correspond to the slight IR-induced increase of MMP-transcription (see above). However cellular pretreatement with patupilone altered neither the basal nor the IR-induced protein level of MMP-2, -3 and −9 in conditioned media (Additional file 2: Figure S2). Thus, the inhibitory, counteracting effect of patupilone on IR-induced MMP activity is not due to downregulation of MMP protein expression or secretion.
Treatment with patupilone prevents the extracellular accumulation of the secreted TIMP-1 and TIMP-2 proteins
Next, we assessed protein levels of TIMP-1 and TIMP-2 in cell lysates and CM derived from the HT1080 fibrosarcoma cells, which were treated with IR and patupilone. In response to irradiation both TIMP-1 and TIMP-2 protein levels were increased in cell lysates and to a higher extent in CM derived from irradiated fibrosarcoma cells when compared to cell lysates and CM derived from control cells (Figure 3B, C). After treatment with patupilone alone, TIMP-1 and TIMP-2 protein levels were slightly elevated in cell lysates, while TIMP protein levels in CM did not change. Interestingly though, pretreatment with patupilone significantly counteracted the level of IR-enhanced TIMP-2-secretion (P = 0.02). A similar but not significant trend was also determined for TIMP-1 after treatment with patupilone in combination with IR (Figure 3B). Complementary to the counteracting effect of patupilone to IR-enhanced TIMP-protein levels in CM, TIMP protein levels in cell lysates were increased after combined treatment with IR and patupilone in comparison to cell lysates derived from cells treated with IR alone (P = 0.04 for TIMP-1; Figure 3C). These results indicate that patupilone does not affect basal and IR-induced TIMP-1 and TIMP-2 expression but rather interferes with IR-enhanced secretion of TIMPs into the CM. Eventually this will result in reduced TIMP-levels in CM in response to the combined treatment modality in comparison to treatment with IR alone.
TIMP-1 and −2 are required to enhance matrix metalloproteinase activity by IR
Additional experiments were perfomed using control (goat IgG) and TIMP-2-directed neutralizing antibodies to confirm the putative regulatory effect of TIMP-2 on the IR-induced MMP-activity. These antibodies were supplemented to the cell culture media during the whole course of the treatment with IR and patupilone and to the serum free cell culture media after irradiation. MMP-activity in CM of control antibody-treated cells increased 1.6-fold in response to irradiation (P = 0.0002). TIMP-2-directed neutralizing antibodies significantly suppressed IR-dependent upregulation of MMP-activity (P = 0.007), to an extent as observed by siRNA-mediated TIMP-2 depletion or by patupilone-pretreatment prior to irradiation alone (see above). Pretreatment of TIMP-depleted cells with patupilone did not result in an additive, counteractive effect with TIMP-directed neutralizing antibodies (Figure 4C).
Thus, extracellular exposure to anti-TIMP-2-directed antibodies had the same neutralizing effect on IR-induced upregulation of MMP activity as siRNA-based depletion of TIMP-1 or TIMP-2, suggesting that TIMP-2 interferes with the MMP-activation process at the extracellular site. Unfortunately no experiments could be performed with neutralizing anti-TIMP-1 antibodies, due to the lack of satisfactory neutralizing activity (based on in vitro evaluation with recombinant TIMP-1 and MMPs; data not shown). Overall, these data indicate that patupilone counteracts IR-upregulated MMP-activity through interference with the TIMP-1 and TIMP-2 protein levels and that it is rather the activating than the inhibitory function of TIMP-1 and TIMP-2 that is involved in the IR-dependent enhancement of MMP-activity.
4-amino-phenylmercuric acetate (APMA) is an organomercuric activator of MMP zymogens, which will fully activate pro-MMPs present in the CM and independent of natural TIMP/MMP activation processes . CMs derived from patupilone and IR-treated HT1080 cells were incubated with APMA (1mM) and MMP activity was determined thereafter. APMA treatment increased the level of MMP activity in all cell culture conditioned media samples (control, patupilone and/or irradiation treated) by 2.1+/−0.16-fold when compared to MMP activity in the corresponding APMA-untreated CMs (P < 0.004). No difference in MMP activity levels was observed between APMA-treated CMs derived from control and patupilone-treated cells. MMP activity in the APMA-incubated CM derived from irradiated cells was further enhanced, when compared to the MMP activity in the APMA-activated control CM (P = 0.02). Interestingly, the MMP activity levels in the APMA-incubated CM derived from irradiated cells and cells treated with the combined treatment modality did not significantly differ. Thus, the counteracting effect of patupilone on IR-induced MMP activity could not anymore be observed after incubation of the respective CMs with APMA (Figure 4D). These results corroborate that patupilone counteracts IR-induced MMP activation presumably on the level of pro-MMP activation processes, since the inhibitory effect of patupilone could no longer be observed when pro-MMPs in the CM were forced into an active state by APMA.
Patupilone inhibits IR-induced cell invasion
Depletion of TIMP-1 and TIMP-2 specifically counteracted IR-dependent upregulation of MMP-activity in the CM (Figure 4C, see above). Importantly depletion of TIMP-1 or TIMP-2 proteins with corresponding siRNAs also specifically abrogated IR-induced cell invasion (Figure 5B, P = 0.007 and 0.02 for siTIMP-1 and −2, respectively). Thus, these results suggest that IR-induced MMP activity translates into IR-enhanced cell invasion. Abrogation of IR-enhanced invasive capacity by patupilone is most probably due to interference with TIMP protein levels and subsequent pro-MMP activation processes.
Here we investigated the regulation of tumor cell-secreted matrix metalloproteinases in response to treatment with the promising combined treatment modality of IR with the clinically relevant MSA patupilone. To our best knowledge we demonstrated for the first time that a microtubule stabilizing agent counteracts IR-enhanced MMP activity and abrogates IR-induced tumor cell invasion. To uncover the molecular mechanism responsible for this counteracting effect, we determined MMP activity under different conditions. Patupilone did not alter IR-induced transcription of MMPs and TIMPs and did not influence intracellular and extracellular protein levels of MMPs. Interestingly though, patupilone counteracted the IR-enhanced cell invasive capacity via reduction of extracellular TIMP-1 and TIMP-2 protein levels, which are required for MMP-activation. The direct involvement of TIMPs in this patupilone-mediated counteracting effect was mechanistically demonstrated by the use of TIMP-neutralizing antibodies and in TIMP-depleted cells.
MMP inhibition represents an interesting strategy for combined treatment with IR, as successfully demonstrated by Kalinski et al. . Previous investigations revealed that patupilone is a potent inhibitor of tumor cell proliferation under hypoxic and normoxic conditions, has anti-angiogenic properties, and radiosensitizes in vivo and in vitro[14, 15, 17, 18, 41–43]. In addition, as demonstrated in this study, patupilone inhibits IR-induced activity of secreted MMPs and IR-induced cell invasiveness. This aspect further increases the potency of patupilone as part of a combined treatment modality with IR and, probably, with other MMP-activating treatment modalities. At the same time these in vitro experiments corroborate our previous investigation on the level of VEGF-secretion that patupilone mechanistically interferes with IR-induced processes on the tumor cell level [14, 19], which eventually strongly contribute to the supra-additive treatment response on the in vivo level.
Gene promoter regions of several MMPs contain putative binding sequences for stress response- and growth factor-induced transcriptional factors such as AP1 and Nf-κB ( and refs therein) and multiple reports confirmed that different stimuli activate MMPs and enhance TIMP protein levels via these pathways. IR was demonstrated to induce MMP-2 and MMP-9 and subsequently cell invasion via activation of the PI3K/Akt/Nf-κB pathways both in vitro and in vivo[30, 31, 40, 44–47]. MSAs may disturb MMP activity and the regulatory function of TIMPs at the level of protein secretion, since intracellular transport of MMPs and TIMPs depends at least in part on an intact MT system [20, 22]. For example, treatment with the MSA paclitaxel impaired secretion of MMP-2 and MMP-9 and significantly reduced the invasion of melanoma cells . TIMPs can not only inhibit but also activate MMPs depending on the ratio of TIMPs and MMPs [48–50]. While TIMP-2 is relevant for processing of pro-MMP-2, the role of TIMP-1 in pro-MMP-9 activation has only been predicted based on the structural similarities of their complexes . In our study, we corroborated that the TIMP/MMP ratio is of great importance for pro-MMP activation and may be deregulated in response to different treatment modalities, and further demonstrated that both TIMP-2 and TIMP-1 are important for MMP activation after radiation treatment. IR failed to enhance MMP activity to a large extent when the protein level of secreted TIMP-1 or TIMP-2 were downregulated by siRNA, neutralizing antibodies or patupilone treatment. Unfortunately and in part due to technical limitations, we could not identify which specific MMP is thereby affected and eventually responsible for the deregulated invasive capacity. Future studies will focus on a putative MMP redundancy and the specific molecular mechanisms of how MSAs and the microtubular dynamics interfere with the intracellular TIMP secretory processes.
MMPs play an important role in cancer progression, remodelling the extracellular matrix and processing multiple biologically active factors. MMPs are upregulated in multiple tumor types and their overexpression correlate with the aggressiveness of the disease. IR-enhanced cell invasion was mainly observed after irradiation with low doses of IR up to 2 Gy. This is most probably due to the concomitant IR-induced cytotoxicity at higher doses, which renders it difficult to differentiate between the two opposing processes. However, cell invasion induced by low radiation doses is of particular importance in the context of fractionated radiation schedules and sub-lethal irradiation of peripheral tumor cells of the radiotherapy treatment volume. Of particular interest is that the counteracting effect of patupilone could also be demonstrated in human glioma cells. Glioblastoma (or grade IV glioma) is one of the most treatment-resistant primary tumors in adults and overall survival still remains at a low rate of 14 months. A major reason for poor prognosis is extensive infiltration of surrounding brain tissue by tumor cells and the blood–brain barrier as an obstacle for the adequate delivery of cytotoxic agents . Radiation therapy is a standard treatment for gliomas and to our best knowledge, we have demonstrated, for the first time, that patupilone can counteract IR-induced activity of secreted MMPs and a subsequent increase of the invasive capacity of glioma cells. The ability of patupilone to cross the blood–brain barrier and to retain in brain tissues  renders patupilone as a single treatment modality a very potent and promising chemotherapeutical agent for brain malignancies . But in addition to the direct cytotoxic and radiosensitizing effect of patupilone, a combined treatment modality of IR with patupilone might minimize the risk for IR-induced glioma cell migration and dissemination, mediated by IR-upregulated MMPs [53, 54]. However, beyond controlling tumor cell dissemination and due to the complex MMP functions in cancer progression and treatment resistance, the combined treatment modality of IR and patupilone might be of a great clinical benefit also for other malignancies.
Previous investigations revealed additive cytotoxicity of IR with the microtubule stabilizing agent patupilone in vitro with a strong supra-additive effect in vivo. Here we mechanistically demonstrate in vitro that patupilone abrogates IR-induced metalloproteinase-activity and IR-induced invasive capacity of tumor cells. Since IR-induced MMP activity may limit tumor control and may even promote tumor progression, these results suggest an additional rationale to combine ionizing radiation with the microtubule interfering agent patupilone. Eventually these in vitro experiments corroborate our previous investigations that patupilone mechanistically interferes with IR-induced processes on the tumor cell level, which might strongly contribute to the supra-additive treatment response on the in vivo level.
We thank Josef Jiricny and Karl-Heinz Altmann for helpful discussions, Paul McSheehy for patupilone and for his continuous support, Bernhard Odermatt and Karl Frei for HT1080 and U251 cells, respectively, and Astrid Jungel and Steffen Gay for the PCR primers. This work was supported by grants from Oncosuisse, Sassella, Novartis, Vontobel and Swiss National Science Foundations (to M. Pruschy).
- Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000, 18: 623-631.PubMedGoogle Scholar
- Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, et al.: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23: 5542-5551. 10.1200/JCO.2005.02.027View ArticlePubMedGoogle Scholar
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351: 1502-1512. 10.1056/NEJMoa040720View ArticlePubMedGoogle Scholar
- Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55: 2325-2333.PubMedGoogle Scholar
- Buey RM, Diaz JF, Andreu JM, O’Brate A, Giannakakou P, Nicolaou KC, Sasmal PK, Ritzen A, Namoto K: Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol 2004, 11: 225-236.PubMedGoogle Scholar
- Risinger AL, Giles FJ, Mooberry SL: Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009, 35: 255-261. 10.1016/j.ctrv.2008.11.001View ArticlePubMedPubMed CentralGoogle Scholar
- Cigler T, Vahdat L: Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting. Clin Breast Cancer 2008,8(Suppl 4):S166-S170.View ArticlePubMedGoogle Scholar
- Fogh S, Machtay M, Werner-Wasik M, Curran WJ Jr, Bonanni R, Axelrod R, Andrews D, Dicker AP: Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010, 77: 1009-1016. 10.1016/j.ijrobp.2009.06.050View ArticlePubMedGoogle Scholar
- Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR: Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009, 20: 492-497.View ArticlePubMedGoogle Scholar
- Rubin EH, Rothermel J, Tesfaye F, Chen T, Hubert M, Ho YY, Hsu CH, Oza AM: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005, 23: 9120-9129. 10.1200/JCO.2005.03.0981View ArticlePubMedGoogle Scholar
- Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lutolf UM, Knuth A, Yonekawa Y, et al.: Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 2012, 83: 1-9. 10.1159/000339152View ArticlePubMedGoogle Scholar
- Alvarez RH, Valero V, Hortobagyi GN: Ixabepilone for the treatment of breast cancer. Ann Med 2011, 43: 477-486. 10.3109/07853890.2011.579151View ArticlePubMedGoogle Scholar
- Kaklamani VG, Xu BH, Gomez HL: Global experience with ixabepilone in breast cancer. Expert Rev Anticancer Ther 2011, 11: 683-692. 10.1586/era.11.41View ArticlePubMedGoogle Scholar
- Bley CR, Jochum W, Orlowski K, Furmanova P, Vuong V, McSheehy PM, Pruschy M: Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res 2009, 15: 1335-1342. 10.1158/1078-0432.CCR-08-0969View ArticlePubMedGoogle Scholar
- Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M: Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005, 11: 1588-1596. 10.1158/1078-0432.CCR-04-1800View ArticlePubMedGoogle Scholar
- Oehler C, von Bueren AO, Furmanova P, Broggini-Tenzer A, Orlowski K, Rutkowski S, Frei K, Grotzer MA, Pruschy M: The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro Oncol 2011, 13: 1000-1010. 10.1093/neuonc/nor069View ArticlePubMedPubMed CentralGoogle Scholar
- Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E: Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 2006, 5: 2348-2357. 10.1158/1535-7163.MCT-06-0242View ArticlePubMedGoogle Scholar
- Ferretti S, Allegrini PR, O’Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, McSheehy PM: Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005, 11: 7773-7784. 10.1158/1078-0432.CCR-05-1165View ArticlePubMedGoogle Scholar
- Rohrer Bley C, Orlowski K, Furmanova P, McSheehy PM, Pruschy M: Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer 2011, 73: 294-301. 10.1016/j.lungcan.2011.01.010View ArticlePubMedGoogle Scholar
- Sbai O, Ferhat L, Bernard A, Gueye Y, Ould-Yahoui A, Thiolloy S, Charrat E, Charton G, Tremblay E, Risso JJ, et al.: Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Mol Cell Neurosci 2008, 39: 549-568. 10.1016/j.mcn.2008.08.004View ArticlePubMedGoogle Scholar
- Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M, Schneider SW: Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 2004, 64: 8924-8931. 10.1158/0008-5472.CAN-04-0324View ArticlePubMedGoogle Scholar
- Stearns ME, Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992, 52: 3776-3781.PubMedGoogle Scholar
- Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2: 161-174. 10.1038/nrc745View ArticlePubMedGoogle Scholar
- Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141: 52-67. 10.1016/j.cell.2010.03.015View ArticlePubMedPubMed CentralGoogle Scholar
- Cruz-Munoz W, Khokha R: The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008, 45: 291-338. 10.1080/10408360801973244View ArticlePubMedGoogle Scholar
- Lichte A, Kolkenbrock H, Tschesche H: The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett 1996, 397: 277-282. 10.1016/S0014-5793(96)01206-9View ArticlePubMedGoogle Scholar
- Lizarraga F, Maldonado V, Melendez-Zajgla J: Tissue inhibitor of metalloproteinases-2 growth-stimulatory activity is mediated by nuclear factor-kappa B in A549 lung epithelial cells. Int J Biochem Cell Biol 2004, 36: 1655-1663. 10.1016/j.biocel.2004.02.004View ArticlePubMedGoogle Scholar
- Guedez L, Courtemanch L, Stetler-Stevenson M: Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998, 92: 1342-1349.PubMedGoogle Scholar
- Lambert E, Bridoux L, Devy J, Dasse E, Sowa ML, Duca L, Hornebeck W, Martiny L, Petitfrere-Charpentier E: TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival. Int J Biochem Cell Biol 2009, 41: 1102-1115. 10.1016/j.biocel.2008.10.017View ArticlePubMedGoogle Scholar
- Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR, Eshhar Z: Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. Prostate 2008, 68: 530-539. 10.1002/pros.20702View ArticlePubMedGoogle Scholar
- Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O’Reilly MS: Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001, 61: 2207-2211.PubMedGoogle Scholar
- Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, Meek AG, Zucker S: Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56: 1161-1169. 10.1016/S0360-3016(03)00161-5View ArticlePubMedGoogle Scholar
- Partridge JJ, Madsen MA, Ardi VC, Papagiannakopoulos T, Kupriyanova TA, Quigley JP, Deryugina EI: Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis. J Biol Chem 2007, 282: 35964-35977. 10.1074/jbc.M705993200View ArticlePubMedGoogle Scholar
- Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000, 60: 2190-2196.PubMedGoogle Scholar
- Broggini-Tenzer A, Hollenstein A, Pianowski Z, Wampfler A, Furmanova P, Winssinger N, Pruschy M: Substrate screening identifies a novel target sequence for the proteasomal activity regulated by ionizing radiation. Proteomics 2010, 10: 304-314. 10.1002/pmic.200900162View ArticlePubMedGoogle Scholar
- Domeij H, Modeer T, Yucel-Lindberg T: Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 production in human gingival fibroblasts: the role of protein kinase C. J Periodontal Res 2004, 39: 308-314. 10.1111/j.1600-0765.2004.00745.xView ArticlePubMedGoogle Scholar
- Park MJ, Park IC, Hur JH, Rhee CH, Choe TB, Yi DH, Hong SI, Lee SH: Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett 2000, 290: 201-204. 10.1016/S0304-3940(00)01358-6View ArticlePubMedGoogle Scholar
- Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253: 269-285. 10.1023/A:1026028303196View ArticlePubMedGoogle Scholar
- Galazka G, Windsor LJ, Birkedal-Hansen H, Engler JA: APMA (4-aminophenylmercuric acetate) activation of stromelysin-1 involves protein interactions in addition to those with cysteine-75 in the propeptide. Biochemistry 1996, 35: 11221-11227. 10.1021/bi960618eView ArticlePubMedGoogle Scholar
- Kaliski A, Maggiorella L, Cengel KA, Mathe D, Rouffiac V, Opolon P, Lassau N, Bourhis J, Deutsch E: Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005, 4: 1717-1728. 10.1158/1535-7163.MCT-05-0179View ArticlePubMedGoogle Scholar
- O’Reilly T, McSheehy PM, Wenger F, Hattenberger M, Muller M, Vaxelaire J, Altmann KH, Wartmann M: Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 2005, 65: 231-240. 10.1002/pros.20289View ArticlePubMedGoogle Scholar
- O’Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM: Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008, 62: 1045-1054. 10.1007/s00280-008-0695-9View ArticlePubMedGoogle Scholar
- Lee SH, Son SM, Son DJ, Kim SM, Kim TJ, Song S, Moon DC, Lee HW, Ryu JC, Yoon DY, Hong JT: Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. Mol Cancer Ther 2007, 6: 2786-2797. 10.1158/1535-7163.MCT-07-0002View ArticlePubMedGoogle Scholar
- Borghaei RC, Gorski G, Javadi M: NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter. Biochem Biophys Res Commun 2009, 382: 269-273. 10.1016/j.bbrc.2009.03.002View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng JC, Chou CH, Kuo ML, Hsieh CY: Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25: 7009-7018. 10.1038/sj.onc.1209706View ArticlePubMedGoogle Scholar
- Lee SK, Kim JM, Lee MY, Son KH, Yeom YI, Kim CH, Shin Y, Koh JS, Han DC, Kwon BM: Confirmation of a linkage between H-Ras and MMP-13 expression as well as MMP-9 by chemical genomic approach. Int J Cancer 2006, 118: 2172-2181. 10.1002/ijc.21610View ArticlePubMedGoogle Scholar
- Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH, Hong SI: Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006, 66: 8511-8519. 10.1158/0008-5472.CAN-05-4340View ArticlePubMedGoogle Scholar
- Butler GS, Hutton M, Wattam BA, Williamson RA, Knauper V, Willenbrock F, Murphy G: The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J Biol Chem 1999, 274: 20391-20396. 10.1074/jbc.274.29.20391View ArticlePubMedGoogle Scholar
- Curry TE Jr, Osteen KG: The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003, 24: 428-465. 10.1210/er.2002-0005View ArticlePubMedGoogle Scholar
- Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270: 5331-5338. 10.1074/jbc.270.10.5331View ArticlePubMedGoogle Scholar
- Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477: 267-283. 10.1016/S0167-4838(99)00279-4View ArticlePubMedGoogle Scholar
- Stupp R, Hegi ME, Gilbert MR, Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007, 25: 4127-4136. 10.1200/JCO.2007.11.8554View ArticlePubMedGoogle Scholar
- Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999, 79: 1828-1835. 10.1038/sj.bjc.6690291View ArticlePubMedPubMed CentralGoogle Scholar
- Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W: Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001, 61: 2744-2750.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.